News
New research reveals GLP-1 drugs like Ozempic may reduce stroke risk and improve recovery. At the 22nd Annual Meeting of the ...
Why can't we sleep? Jennifer Senior, a senior staff writer at The Atlantic, talks about the stigma around sleeping pills.
Time Walker on MSN19h
Exploring Shenzhen’s Fortune 500 company district on foot 4KThis walking tour explores Shenzhen’s corporate landscape, developed for global firms and regional headquarters.
Eating disorder centers are facing an influx of people with weight-loss prescriptions. Experts say doctors are ...
GLP-1 drugs like Ozempic have already become a game-changer for obesity and diabetes. But new research shows they may also ...
Welcome to our live blog tracking the latest news and developments from Canada. Stay updated with real-time insights into the ...
But more big tests loom with trade talks still continuing between the Trump administration and counterparts in China and the ...
GLP-1s - which mimic the effects of the hormone that stimulates insulin release, suppressing glucagon, and slowing gastric emptying - also have a range of other benefits.
Novo Nordisk sees 65% obesity drug sales growth, forecasts $8.14–$9.59B FY25 free cash flow. Click here to read an analysis ...
Discover how food brands can adapt to the rising GLP-1 trend. As weight-loss drugs reshape consumer habits, learn which ...
European stock markets are ripping. The numbers have surprised nearly everyone. During the first half of the year, European stocks outpaced their American peers by the widest margin on record (in U.S.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results